
|Videos|August 3, 2015
Will Biosimilars Impact the Cost of Specialty Drugs?
Author(s)Davy James, Managing Editor
Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.
Advertisement
Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
3
Workforce Preparation for Fall Immunization Season Starts Now
4
Clinical Forum Events Highlight the Evolving Landscape of Obesity Management
5






































































































